Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dicot Pharma ABFRA:KN0 +1.35%18 3-1 Month Momentum % is -15.79% as of Sep. 22, 2026. GuruFocus rates FRA:KN0 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 1,018 Drug Manufacturers companies, Dicot Pharma AB ranks worse than 75.83% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Dicot Pharma AB's 3-1 Month Momentum % is -15.79%.
The industry rank for Dicot Pharma AB's 3-1 Month Momentum % or its related term are showing as below:
FRA:KN0's 3-1 Month Momentum % is ranked worse than 75.83% of 1018
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs FRA:KN0: -15.79
Dicot Pharma AB (FRA:KN0) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Dicot Pharma AB 3-1 Month Momentum % Related Terms
FRA:KN0 vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dicot Pharma AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicot Pharma AB 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dicot Pharma AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Dicot Pharma AB's 3-1 Month Momentum % falls into.
Dicot Pharma AB (FRA:KN0) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicot Pharma AB (FRA:KN0) has a 3-1 Month Momentum % of -15.79% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dicot Pharma AB and its competitors. According to the industry distribution chart, Dicot Pharma AB ranks #772 out of 1018 companies in the Drug Manufacturers industry, placing it in the top 75.8%.
Is Dicot Pharma AB's 3-1 Month Momentum % too high?
Dicot Pharma AB's current 3-1 Month Momentum % is -15.79%. Based on the distribution chart, Dicot Pharma AB ranks #772 out of 1018 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dicot Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Dicot Pharma AB's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dicot Pharma AB ranks #772 out of 1018 companies for 3-1 Month Momentum %. This places Dicot Pharma AB in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.33, based on 1,018 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Dicot Pharma AB and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dicot Pharma AB's current 3-1 Month Momentum % is -15.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dicot Pharma AB stock overvalued right now?
Dicot Pharma AB (FRA:KN0) has a current 3-1 Month Momentum % of -15.79%. The current 3-1 Month Momentum % is -15.79%. Dicot Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Dicot Pharma AB (FRA:KN0), the current 3-1 Month Momentum % is -15.79% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dicot Pharma AB is a Swedish pharmaceutical research and development company focused on treatments for sexual dysfunction. Its lead drug candidate, LIB-01, is being developed as an oral therapy for erectile dysfunction and premature ejaculation, with the aim of offering a longer duration of action and a more favorable side-effect profile than existing treatments. The company operates a drug development business model rather than a commercial sales model, advancing LIB-01 through preclinical and clinical testing while evaluating industrial and financial partnerships to fund development and eventual commercialization. Dicot Pharma is based in Sweden and targets the global market for sexual dysfunction therapies, with potential licensing or partnership agreements serving as its primary route to revenue. As a development-stage company, it does not currently generate product sales.
18GF Score
Get the complete analysis for FRA:KN0
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN0 has been successfully added to your 
